Literature DB >> 23301189

Erythropoietin and autoimmune neuroinflammation: lessons from experimental autoimmune encephalomyelitis and experimental autoimmune neuritis.

Taekyun Shin1, Meejung Ahn, Changjong Moon, Seungjoon Kim.   

Abstract

Erythropoietin (EPO) is known to have numerous biological functions. While its primary function is during haematopoiesis, recent studies have shown that EPO plays important role in cytoprotection, immunomodulation, and antiapoptosis. These secondary functions of EPO are integral to tissue protection following hypoxic injury, ischemia-reperfusion injury, and spinal cord injury in the central nervous system. This review focuses on experimental evidence documenting the neuroprotective effects of EPO in organ-specific autoimmune nervous system disorders such as experimental autoimmune encephalomyelitis (EAE) and experimental autoimmune neuritis (EAN). In addition, the immunomodulatory role of EPO in the pathogenesis of EAE and EAN animal models of human multiple sclerosis and Guillain-Barré syndrome, respectively, will be discussed.

Entities:  

Keywords:  Autoimmune diseases; Encephalomyelitis; Erythropoietin; Experimental autoimmune neuritis; Neuroinflammation; Neuroprotection

Year:  2012        PMID: 23301189      PMCID: PMC3531585          DOI: 10.5115/acb.2012.45.4.215

Source DB:  PubMed          Journal:  Anat Cell Biol        ISSN: 2093-3665


  55 in total

1.  Altered M1/M2 activation patterns of monocytes in severe relapsing experimental rat model of multiple sclerosis. Amelioration of clinical status by M2 activated monocyte administration.

Authors:  Joanna Mikita; Nadège Dubourdieu-Cassagno; Mathilde Sa Deloire; Antoine Vekris; Marc Biran; Gérard Raffard; Bruno Brochet; Marie-Hélène Canron; Jean-Michel Franconi; Claudine Boiziau; Klaus G Petry
Journal:  Mult Scler       Date:  2010-09-02       Impact factor: 6.312

Review 2.  Lessons from multiple sclerosis: models, concepts, observations.

Authors:  H Wekerle
Journal:  Ann Rheum Dis       Date:  2008-12       Impact factor: 19.103

3.  Delayed administration of erythropoietin and its non-erythropoietic derivatives ameliorates chronic murine autoimmune encephalomyelitis.

Authors:  Costanza Savino; Rosetta Pedotti; Fulvio Baggi; Federica Ubiali; Barbara Gallo; Sara Nava; Paolo Bigini; Sara Barbera; Elena Fumagalli; Tiziana Mennini; Annamaria Vezzani; Massimo Rizzi; Thomas Coleman; Anthony Cerami; Michael Brines; Pietro Ghezzi; Roberto Bianchi
Journal:  J Neuroimmunol       Date:  2005-12-07       Impact factor: 3.478

Review 4.  The role of cytokines in Guillain-Barré syndrome.

Authors:  Ming-Ou Lu; Jie Zhu
Journal:  J Neurol       Date:  2010-11-23       Impact factor: 4.849

5.  Expression of constitutive endothelial and inducible nitric oxide synthase in the sciatic nerve of Lewis rats with experimental autoimmune neuritis.

Authors:  Yongduk Lee; Taekyun Shin
Journal:  J Neuroimmunol       Date:  2002-05       Impact factor: 3.478

6.  Anti-inflammatory effect of erythropoietin therapy on experimental autoimmune encephalomyelitis.

Authors:  Xiang Zhang; Qin-Ying Li; Bao-Guo Xiao
Journal:  Int J Neurosci       Date:  2012-02-06       Impact factor: 2.292

Review 7.  Heme oxygenase-1 as a therapeutic target in neurodegenerative diseases and brain infections.

Authors:  Antonio Cuadrado; Ana I Rojo
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

8.  Endogenous erythropoietin as part of the cytokine network in the pathogenesis of experimental autoimmune encephalomyelitis.

Authors:  Manuela Mengozzi; Ilaria Cervellini; Paolo Bigini; Sara Martone; Antonella Biondi; Rosetta Pedotti; Barbara Gallo; Sara Barbera; Tiziana Mennini; Mariaserena Boraso; Marina Marinovich; Edwige Petit; Myriam Bernaudin; Roberto Bianchi; Barbara Viviani; Pietro Ghezzi
Journal:  Mol Med       Date:  2008-07-30       Impact factor: 6.354

Review 9.  Erythropoietin and the brain: from neurodevelopment to neuroprotection.

Authors:  M Buemi; E Cavallaro; F Floccari; A Sturiale; C Aloisi; M Trimarchi; G Grasso; F Corica; N Frisina
Journal:  Clin Sci (Lond)       Date:  2002-09       Impact factor: 6.124

10.  Mechanism of experimental autoimmune encephalomyelitis in Lewis rats: recent insights from macrophages.

Authors:  Taekyun Shin; Meejung Ahn; Yoh Matsumoto
Journal:  Anat Cell Biol       Date:  2012-09-30
View more
  6 in total

1.  Effects of erythropoietin preconditioning on rat cerebral ischemia-reperfusion injury and the GLT-1/GLAST pathway.

Authors:  Daihua Yu; Yuanhua Fan; Xude Sun; Linong Yao; Wei Chai
Journal:  Exp Ther Med       Date:  2015-12-08       Impact factor: 2.447

2.  A double-blind, placebo-controlled trial of adding erythropoietin to intravenous methylprednisolone for the treatment of unilateral acute optic neuritis of unknown or demyelinative origin.

Authors:  Vahid Shayegannejad; Shima Shahzamani; Alireza Dehghani; Zahra Dast Borhan; Marzie Rahimi; Arash Mirmohammadsadeghi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-01-22       Impact factor: 3.117

3.  Erythropoietin-derived nonerythropoietic peptide ameliorates experimental autoimmune neuritis by inflammation suppression and tissue protection.

Authors:  Yuqi Liu; Bangwei Luo; Fuyu Han; Xiaoming Li; Jian Xiong; Man Jiang; Xioafeng Yang; Yuzhang Wu; Zhiren Zhang
Journal:  PLoS One       Date:  2014-03-06       Impact factor: 3.240

4.  Epobis is a Nonerythropoietic and Neuroprotective Agonist of the Erythropoietin Receptor with Anti-Inflammatory and Memory Enhancing Effects.

Authors:  Oksana Dmytriyeva; Stanislava Pankratova; Irina Korshunova; Peter S Walmod
Journal:  Mediators Inflamm       Date:  2016-11-21       Impact factor: 4.711

5.  Expanding the Potential Therapeutic Options for Remote Ischemic Preconditioning: Use in Multiple Sclerosis.

Authors:  Carlos R Camara-Lemarroy; Luanne Metz; Eric E Smith; Jeff F Dunn; V Wee Yong
Journal:  Front Neurol       Date:  2018-06-19       Impact factor: 4.003

Review 6.  Neocytolysis: none, one or many? A reappraisal and future perspectives.

Authors:  Angela Risso; Annarita Ciana; Cesare Achilli; Guglielmo Antonutto; Giampaolo Minetti
Journal:  Front Physiol       Date:  2014-02-14       Impact factor: 4.566

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.